Taysha Gene Therapies, Inc.
TSHA
$2.31
-$0.07-2.94%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 26.47% | 19.96% | 89.38% | 7.66% | 11.49% |
| Total Depreciation and Amortization | -11.87% | -9.19% | -4.39% | 2.36% | 9.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -65.20% | -64.48% | -128.09% | -2.95% | 5.48% |
| Change in Net Operating Assets | -36.20% | 30.79% | -197.01% | -208.79% | -210.73% |
| Cash from Operations | -14.89% | -11.24% | -87.33% | -42.07% | -7.39% |
| Capital Expenditure | -461.47% | 90.33% | 93.62% | 95.62% | 99.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.52% | 100.32% | 100.20% | -228.28% | -165.68% |
| Cash from Investing | 83.46% | 95.06% | 96.03% | 58.44% | 79.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -45.29% | -45.34% | -57.77% | 401.11% | 164.83% |
| Repurchase of Common Stock | 14.89% | 14.89% | -- | -522.06% | -522.06% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 58.94% | 81.77% | 44.37% | 43.89% | 55.22% |
| Cash from Financing | -43.94% | -43.78% | -59.98% | 402.80% | 163.81% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -112.21% | -108.75% | -105.10% | 703.25% | 282.26% |